Investors

Press Releases

 
Press Releases
  Date Title View
Sep 11, 2017
- Top-line Data Expected in 1Q 2018 - - IGNITE3 Results to Support U.S. sNDA Filing for IV Eravacycline in cUTI - WATERTOWN, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) inf...
Sep 5, 2017
WATERTOWN, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will present at the following upcoming investor conferences: Rodm...
Aug 17, 2017
WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of com...
Aug 2, 2017
WATERTOWN, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the second quarter ended June 30, 2017 and provided an overview of recent a...
Jul 27, 2017
WATERTOWN, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock for a pu...
Jul 26, 2017
WATERTOWN, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it has commenced an underwritten offering of $60,000,000 of shares of its common stock. All...
Jul 25, 2017
̶   IV Eravacycline Achieves Primary Endpoint in Second of Two Pivotal Trials in cIAI  ̶ ̶   Company Proceeding with Regulatory Submissions in Europe in 3Q 2017 and U.S. in 1Q 2018   ̶  ̶  Ongoing Phase 3 IGNITE3 Clinical Trial in cUTI Expected to Complete Enrollment Early 4Q 2017  ̶ ̶   Conference Call Sch...
Jun 5, 2017
WATERTOWN, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive data from phase 1 single-ascending dose studies for its two pipeline programs, TP-6076 ...
May 30, 2017
WATERTOWN, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the Jefferies 2017 Global Healthcare...
May 22, 2017
Eleven Abstracts Selected for Presentation, Including Four Highlighting Pharmacokinetic and Global Surveillance Data for Eravacycline TP-6076 Phase 1 Single-Ascending Dose Data Selected for Oral Presentation; TP-271 Phase 1 Single-Ascending Dose Data to be Featured in Poster Presentation WATERTOWN, Mass., May 22, 2017 (GLOBE NEWSWIRE) --  T...
1
...
NextLast
= add release to Briefcase